Literature DB >> 11397872

Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level.

U Pagotto1, G Marsicano, F Fezza, M Theodoropoulou, Y Grübler, J Stalla, T Arzberger, A Milone, M Losa, V Di Marzo, B Lutz, G K Stalla.   

Abstract

Little is known about the expression and function of cannabinoid receptor type 1 (CB1) in the human pituitary gland. The aim of this study was to investigate CB1 expression in human normal and tumoral pituitaries by in situ hybridization and immunohistochemistry using an antibody against CB1. CB1 was found in corticotrophs, mammotrophs, somatotrophs, and folliculostellate cells in the anterior lobe of normal pituitary. After examination of 42 pituitary adenomas, CB1 was detected in acromegaly-associated pituitary adenomas, Cushing's adenomas, and prolactinomas, whereas faint or no expression was found in nonfunctioning pituitary adenomas. Experiments with cultured pituitary adenoma cells showed that the CB1 agonist WIN 55,212--2 inhibited GH secretion in most of acromegaly-associated pituitary adenomas tested and that the CB1 antagonist SR 141716A was generally able to reverse this effect. Moreover, WIN 55,212--2 was able to suppress GHRH-stimulated GH release, and this effect was not blocked by coincubation with SR 141716A, possibly indicating a non-CB1-mediated effect. In contrast, WIN 55,212--2 was ineffective on GH-releasing peptide-stimulated GH release. In four Cushing's adenomas tested, WIN 55,212--2 was not able to modify basal ACTH secretion. However, simultaneous application of CRF and WIN 55,212--2 resulted in a synergistic effect on ACTH secretion, and this effect could be abolished by SR 141716A, demonstrating a CB1-mediated effect. In the single case of prolactinomas tested, WIN 55,212--2 was able to inhibit basal secretion of PRL. Finally, the presence of endocannabinoids (anandamide and 2-arachidonoylglycerol) was investigated in normal and tumoral pituitaries. All tumoral samples had higher contents of anandamide and 2-arachidonoylglycerol compared with the normal hypophysis. Moreover, endocannabinoid content in the different pituitary adenomas correlated with the presence of CB1, being elevated in the tumoral samples positive for CB1 and lower in the samples in which no or low levels of CB1 were found. The results of this study point to a direct role of cannabinoids in the regulation of human pituitary hormone secretion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397872     DOI: 10.1210/jcem.86.6.7565

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Neuroendocrine regulation of eating behavior.

Authors:  R Vettor; R Fabris; C Pagano; G Federspil
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

Review 2.  Endocannabinoids and the Endocrine System in Health and Disease.

Authors:  Cecilia J Hillard
Journal:  Handb Exp Pharmacol       Date:  2015

Review 3.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

4.  Immunohistochemical localization of CB1 receptor in canine salivary glands.

Authors:  C Dall'Aglio; F Mercati; L Pascucci; C Boiti; V Pedini; P Ceccarelli
Journal:  Vet Res Commun       Date:  2010-06       Impact factor: 2.459

Review 5.  Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis.

Authors:  M N Hill; J G Tasker
Journal:  Neuroscience       Date:  2011-12-24       Impact factor: 3.590

Review 6.  Cannabinoids, endocannabinoids, and cancer.

Authors:  Daniel J Hermanson; Lawrence J Marnett
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 7.  Endocannabinoid Signaling and the Hypothalamic-Pituitary-Adrenal Axis.

Authors:  Cecilia J Hillard; Margaret Beatka; Jenna Sarvaideo
Journal:  Compr Physiol       Date:  2016-12-06       Impact factor: 9.090

Review 8.  POMC: The Physiological Power of Hormone Processing.

Authors:  Erika Harno; Thanuja Gali Ramamoorthy; Anthony P Coll; Anne White
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

Review 9.  Cannabinoid signalling and effects of cannabis on the male reproductive system.

Authors:  Mauro Maccarrone; Cinzia Rapino; Felice Francavilla; Arcangelo Barbonetti
Journal:  Nat Rev Urol       Date:  2020-11-19       Impact factor: 14.432

Review 10.  Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch.

Authors:  Renato Malcher-Lopes; Alier Franco; Jeffrey G Tasker
Journal:  Eur J Pharmacol       Date:  2008-01-31       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.